STTKHealthcare · BiotechnologyThe 12 Wall Street analysts covering Shattuck Labs, Inc. hold a median 12-month price target of $16 — +190.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Shattuck Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Volatility (29): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STTK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +190.8% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Oct 2026 | Needham | Maintains | Buy | $17 → $19 |
| 2 Oct 2026 | Wedbush | Maintains | Outperform | $11 → $14 |
| 24 Aug 2026 | Raymond James | Initiates | Strong Buy | — |
| 24 Aug 2026 | Raymond James | Initiates | Strong Buy | $18 |
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $18 → $14 |
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 July 2026 | JP Morgan | Initiates | Overweight | $10 |
| 24 July 2026 | JP Morgan | Initiates | Overweight | — |
| 20 July 2026 | Leerink Partners | Initiates | Outperform | $16 |
| 20 July 2026 | Leerink Partners | Initiates | Outperform | — |
| 9 June 2026 | Citigroup | Maintains | Buy | — |
| 9 June 2026 | Citigroup | Maintains | Buy | $7.00 → $18 |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $18 |
| 8 June 2026 | Needham | Maintains | Buy | — |
| 8 June 2026 | Needham | Maintains | Buy | $14 → $17 |
| 5 June 2026 | Citigroup | Upgrade | Buy | — |
| 5 June 2026 | Citigroup | Upgrade | Buy | $7.00 |
| 8 May 2026 | Wedbush | Maintains | Outperform | — |
| 27 Apr 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STTK appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Shattuck Labs, Inc. returned +185.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 1% of US stocks
Cheaper than 34% of US stocks
Cheaper than 82% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Shattuck Labs, Inc. has a market value of $551.0M and an enterprise value of $345.4M.
Revenue in the twelve months to 30 June 2026: $1.0M.
Net income over the same four quarters: −$52.6M, a −5256.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.51.
Free cash flow in the twelve months to 30 June 2026: −$41.2M.
Trailing P/E: −7.8×; forward P/E: −10.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Shattuck Labs, Inc. employs 40 people — $25K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Shattuck Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Shattuck Labs announced that it will give two poster presentations at UEG Week 2026, taking place October 17–20 in Barcelona, Spain.
Why it matters — The presentations will share Shattuck’s research at a gastroenterology meeting, relevant to watchers tracking its development of DR3-blocking antibodies for inflammatory and immune-mediated diseases.
Shattuck Labs announced plans for a Phase 2 clinical trial, RECEPTIVE-HS1, evaluating SL-325 in patients with moderate to severe hidradenitis suppurativa, with initiation expected in 2026 and 16-week data expected in the first half of 2028. The company also announced the appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development, to lead the HS program, while confirming its cash runway guidance remains unchanged with existing cash expected to fund operations into 2029.
Why it matters — This expands SL-325 into a second Phase 2 indication beyond IBD, broadening the company's pipeline in inflammatory diseases with a dedicated clinical development lead appointed and cash runway guidance maintained.
Shattuck Labs announced that company management will present at and participate in several upcoming investor conferences in September. The announcement was made via a press release on September 2, 2026.
Why it matters — This indicates that Shattuck Labs management will be engaging with the investment community, which could raise the company's visibility among investors.
Shattuck Labs has pivoted to immunology, focusing on DR3-targeted therapies for IBD, particularly SL-325, after discontinuing its oncology program. Early Phase 1 data for SL-325 show strong safety, low immunogenicity, and durable receptor occupancy supporting quarterly dosing, with the company fully funded through the Phase 2b efficacy readout and cash runway into 2029.
Why it matters — A Shattuck Labs watcher would care because SL-325's favorable Phase 1 profile and funded runway position the company's IBD-focused pipeline toward an upcoming Phase 2b efficacy signal, a key catalyst for the stock.
Shattuck Labs stock outperformed the market on Monday. According to the report, one party initiated coverage of the company, which has a very promising lead drug candidate.
Why it matters — A STTK watcher would care because fresh coverage initiation and a promising lead drug candidate may bring renewed attention to the company's pipeline.
The 12 Wall Street analysts covering Shattuck Labs, Inc. have a median 12-month price target of $16, with estimates ranging from $10 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Shattuck Labs, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Shattuck Labs, Inc. 71 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Shattuck Labs, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +190.8% from the last close, and Ticker Nerd's factor model ranks Shattuck Labs, Inc. 71 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Shattuck Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STTK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $19 over the next 12 months.
Shattuck Labs, Inc. returned +185.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory and immune-mediated diseases.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Shattuck Labs Announces Two Poster Presentations at UEG Week 2026". Shattuck Labs announced that it will give two poster presentations at UEG Week 2026, taking place October 17–20 in Barcelona, Spain.
Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory and immune-mediated diseases. The company’s lead program centers on SL-325, a DR3 antagonist antibody designed to target the TL1A/DR3 pathway, which is being studied for inflammatory bowel disease and related conditions. Shattuck Labs is also advancing SL-425, a half-life extended version of SL-325, along with additional preclinical DR3-based antibody candidates. Its research is built around protein engineering and novel therapeutic designs intended to modulate immune signaling more precisely. Based in Austin, Texas, Shattuck Labs operates within the broader biopharmaceutical market, where its current pipeline is aimed at addressing immune-driven diseases with significant unmet medical need.
CEO Dr. Taylor H. Schreiber M.D., Ph.D. · 40 employees · United States · https://www.shattucklabs.com
